Hiroyuki Nakamura

This inventor holds 5 USPTO granted patents. Top assignees: Chiba University, Megachips Corporation. Active years: 2015-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroyuki Nakamura. Retrieved from https://idiyas.com/inventor/hiroyuki-nakamura-tus5sp0v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5

% Patents Active = 80.0

Average Co-Inventor Count = 1.5

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

Megachips Corporation

patents

Years Active: 2015-2021

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10980789 - Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated Smad (2021-04-20),

2. 10478427 - Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad (2019-11-19),

3. 10215808 - Scan test circuit, scan test method, and method of designing scan test circuit (2019-02-26),

4. 10083759 - Testing circuit for semiconductor integrated circuit and testing method using the same (2018-09-25),

5. 9207232 - Ceramide derivative and Golgi apparatus-labeling fluorescent probe using same (2015-12-08),

Title: Hiroyuki Nakamura: Innovator in Therapeutic Agents for Fibrosis

Introduction

Hiroyuki Nakamura is a prominent inventor based in Chiba, Japan. He has made significant contributions to the field of therapeutic agents, particularly in the treatment of fibrosis. With a total of 5 patents to his name, Nakamura's work has the potential to impact many lives.

Latest Patents

Nakamura's latest patents focus on a therapeutic agent for fibrosis. This agent's active ingredient consists of a glucosylceramide synthase inhibitor or a lactosylceramide synthase inhibitor, or both. These inhibitors work by preventing the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis. His innovative approach offers new hope for those affected by this condition.

Career Highlights

Throughout his career, Nakamura has been associated with notable institutions such as Chiba University and Megachips Corporation. His work in these organizations has allowed him to develop and refine his inventions, contributing to advancements in medical therapies.

Collaborations

Nakamura has collaborated with esteemed colleagues, including Toshihiko Murayama and Atsushi Nishida. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Hiroyuki Nakamura's contributions to the field of therapeutic agents for fibrosis demonstrate his commitment to advancing medical science. His innovative patents and collaborations highlight the importance of teamwork in achieving breakthroughs in healthcare.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]